Kathya Chartre
Family Medicine · Chicago, ILNPI 1174831168
Payments from drug & device makers
Across 485 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$3K
- Gilead$2K
- Novo Nordisk$704
- AbbVie$618
- Merck$585
- Theratechnologies Inc.$430
- plus $2K from 19 others
Across 16 payments — averaging $121.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$2K
- GSK$196
What the payments were for
- Food & beverage$9,139100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 171 | $3,035 |
| Gilead | 96 | $1,936 |
| Novo Nordisk | 36 | $704 |
| AbbVie(2 entities) | 30 | $618 |
| Merck | 26 | $585 |
| Theratechnologies Inc. | 25 | $430 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $330 |
| Teva Pharmaceuticals USA, Inc. | 20 | $310 |
| Biohaven Pharmaceuticals, Inc. | 8 | $207 |
| Johnson & Johnson | 9 | $177 |
| Napo Pharmaceuticals Inc | 11 | $170 |
| Lilly USA, LLC | 9 | $162 |
| Pfizer | 4 | $74 |
| EMD Serono, Inc. | 4 | $64 |
| Redhill Biopharma Inc. | 2 | $50 |
| Phadia US Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Amgen | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Seqirus USA Inc | 2 | $37 |
| Lundbeck LLC | 1 | $22 |
| Adlon Therapeutics L.p. | 1 | $19 |
| GSK | 1 | $17 |
| Bioventus LLC | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,139 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 19 | $77,176 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $33,870 |
| Amlodipine Besylate | 18 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,936 | $111,04631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Chicago
- Bradley TorphyChicago$3M
- Frank PhillipsChicago$1.6M
- Ayoade AkereChicago$484K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
- Jacqueline OlivoChicago$165K
- Sameer PanjwaniChicago$136K
- Igor AltmanChicago$64K
- Juan RojasChicago$40K
- Mark SimonChicago$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.